2009
DOI: 10.1016/j.ejphar.2009.09.032
|View full text |Cite
|
Sign up to set email alerts
|

Myocardial protection by F 15845, a persistent sodium current blocker, in an ischemia-reperfusion model in the pig

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2011
2011
2015
2015

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 9 publications
(3 citation statements)
references
References 22 publications
0
3
0
Order By: Relevance
“…The combined blockade of peripheral nociceptive signaling pathways, such as the Anti-ischemic in vivo models; myocardial infarction acute model [364][365][366][367] Pyrazines 2010 Na v 1.8 Spinal nerve ligation model of neuropathic pain [252] Isoxazoles 2009 Na v 1.7 Spinal nerve ligation model of neuropathic pain [242] Isoxazolines [289] [a] Preclinical small molecules claimed to have inhibitory activity against a given Na v 1.X subtypes for which bibliographic information could not be retrieved: Neu-P12 (Na v 1.7/Na v 1.3), [368] CR4892 (Na v 1.8). One potential strategy of differentiation from these highly brain-penetrant compounds could be envisaged in the avoidance of the CNS-mediated side effects by means of a peripheral compound.…”
Section: Individual Subtypes As Drug Targetsmentioning
confidence: 99%
“…The combined blockade of peripheral nociceptive signaling pathways, such as the Anti-ischemic in vivo models; myocardial infarction acute model [364][365][366][367] Pyrazines 2010 Na v 1.8 Spinal nerve ligation model of neuropathic pain [252] Isoxazoles 2009 Na v 1.7 Spinal nerve ligation model of neuropathic pain [242] Isoxazolines [289] [a] Preclinical small molecules claimed to have inhibitory activity against a given Na v 1.X subtypes for which bibliographic information could not be retrieved: Neu-P12 (Na v 1.7/Na v 1.3), [368] CR4892 (Na v 1.8). One potential strategy of differentiation from these highly brain-penetrant compounds could be envisaged in the avoidance of the CNS-mediated side effects by means of a peripheral compound.…”
Section: Individual Subtypes As Drug Targetsmentioning
confidence: 99%
“…Infarct size was measured by plasma levels of myoglobin and troponin I plasma levels, as well as by tetrazolium staining of the heart at sacrifice. Blockade of the persistent (late) sodium current by F 15845 resulted in a reduction of infarct size by 43 % in treated pigs [24].…”
Section: In Vivo Heart Modelsmentioning
confidence: 98%
“…In rabbits subjected to 5 min coronary artery occlusion and in dogs with coronary stenosis and subjected to left atrial pacing F15845 dose-dependently inhibited ischamia-induced ST segment elevation [ 51 ]. The myocardial protection afforded by F15845 was assessed in two pig models of I/R [ 54 ]. In the first model, the left circumflex coronary artery (LCCA) was ligated for 60-min and then reperfused for 48-h and F15845 administered i.v.…”
Section: F15845mentioning
confidence: 99%